Olema Pharmaceuticals OLMA
$ 8.79
11.69%
Quarterly report 2024-Q3
added 11-12-2024
Olema Pharmaceuticals Balance Sheet 2011-2024 | OLMA
Annual Balance Sheet Olema Pharmaceuticals
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-66.1 M | -21.1 M | -10.5 M | -339 M | -68 K | -3.15 M | - | - | - | - | - | - | - |
Long Term Debt |
1.43 M | 1.55 M | 2.36 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
988 K | 1.02 M | 931 K | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 9.35 M | 9.35 M | - | - | - | - | - | - | - |
Total Current Liabilities |
21.6 M | 16.5 M | 9.02 M | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
23 M | 18.1 M | 11.4 M | 4.58 M | 10.7 M | 9.55 M | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-306 M | -209 M | -104 M | - | -10.8 M | -6.45 M | - | - | - | - | - | - | - |
Total Assets |
277 M | 216 M | 296 M | 343 M | 132 K | 3.27 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
68.5 M | 23.7 M | 13.8 M | 339 M | - | - | - | - | - | - | - | - | - |
Book Value |
254 M | 198 M | 285 M | 338 M | -10.6 M | -6.28 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
254 M | 198 M | 285 M | 338 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Olema Pharmaceuticals
2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
562 K | 859 K | 1.15 M | 1.43 M | 1.7 M | 1.21 M | 1.38 M | 1.55 M | 1.75 M | 2.01 M | 2.16 M | 2.36 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
31.3 M | 27.4 M | 27.4 M | 23 M | 17.7 M | 16 M | 20.8 M | 18.1 M | 14.3 M | 14.3 M | 12.3 M | 11.4 M | 8.9 M | 8.15 M | 5.28 M | 4.58 M | 4.58 M | 4.58 M | 4.58 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-402 M | -367 M | -337 M | -306 M | -279 M | -257 M | -237 M | -209 M | -183 M | -160 M | -127 M | -104 M | -82.6 M | -64.8 M | -48.4 M | -33.1 M | -33.1 M | -33.1 M | -33.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
230 M | 255 M | 264 M | 277 M | 293 M | 178 M | 196 M | 216 M | 232 M | 251 M | 277 M | 296 M | 310 M | 322 M | 331 M | 343 M | 343 M | 343 M | 343 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
35.9 M | 16.9 M | 33.7 M | 68.5 M | 117 M | 35 M | 40.9 M | 23.7 M | 26.8 M | 24.5 M | 21.5 M | 13.8 M | 25.6 M | 50.4 M | 47.9 M | 339 M | 339 M | 339 M | 339 M | 68 K | - | - | - | 3.15 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
199 M | 227 M | 236 M | 254 M | 275 M | 162 M | 175 M | 198 M | 218 M | 236 M | 265 M | 285 M | 301 M | 314 M | 326 M | 338 M | 338 M | 338 M | 338 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
199 M | 227 M | 236 M | 254 M | 275 M | 162 M | 175 M | 198 M | 218 M | 236 M | 265 M | 285 M | 301 M | 314 M | 326 M | 338 M | 338 M | 338 M | 338 M | -10.6 M | - | - | - | -8.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency